rogaratinib
Small moleculeexperimental
Clinical trial activity
13 trials · 13 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Dec 30, 2013 (NCT01976741)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Transitional Cell · Phase 2/Phase 3
- Clinical Trial, Phase I · Phase 1
- Gastrointestinal Stromal Tumors · Phase 2
- Hamartoma · Phase 2
- Intestinal Neoplasms · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Pharmacokinetics · Phase 1
- Sarcoma · Phase 2
- Stomach Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 2
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
COCc1c(-c2cc3cc(C)cc(OC)c3s2)c2c(N)ncnn2c1CN1CCNC(=O)C1- Mol. weight
- 466.57 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3963485 ↗
- ChEMBLCHEMBL3545361 ↗
Also known as
- bay-1163877
- bay-1163877
- rogaratinib
- rogaratinib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04595747 | Phase 2 | Jan 8, 2021 | Harvard University, National Cancer Institute (NCI) |
| NCT04483505 | Phase 1 | Nov 25, 2020 | Apices Soluciones S.L., Bayer, Centro Nacional de Investigaciones Oncológicas, Fundacion CRIS de Investigación para Vencer el Cáncer, Pfizer, Universidad Autonoma de Madrid, Universidad Complutense de Madrid |
| NCT04125693 | Phase 2 | Oct 22, 2019 | Bayer |
| NCT04077255 | Phase 2 | Sep 1, 2019 | National Cancer Center, Korea, Seoul National University |
| NCT04040725 | Phase 2 | Aug 31, 2019 | Bayer, Harvard University |
| NCT03762122 | Phase 2 | Jun 30, 2019 | Swiss Group for Clinical Cancer Research, University of Geneva |
| NCT03788603 | Phase 1 | Jan 7, 2019 | Bayer |
| NCT03517956 | Phase 1 | Jul 25, 2018 | Bayer |
| NCT03410693 | Phase 2/Phase 3 (Phase 3) | May 31, 2018 | Bayer |
| NCT03473756 | Phase 1/Phase 2 (Phase 2) | May 15, 2018 | Bayer |
| NCT03484585 | Phase 1 | Apr 6, 2018 | Bayer |
| NCT02592785 | Phase 1 | Dec 15, 2015 | Bayer |
| NCT01976741 | Phase 1 | Dec 30, 2013 | Bayer |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 10 | 8 | 3 | 2013 |
| Harvard University | Academic/Hospital | 2 | 1 | 1 | 2019 |
| Apices Soluciones S.L. | For profit | 1 | 0 | 1 | 2020 |
| Centro Nacional de Investigaciones Oncológicas | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Fundacion CRIS de Investigación para Vencer el Cáncer | Academic/Hospital | 1 | 1 | 1 | 2020 |
| National Cancer Center, Korea | Government | 1 | 1 | 1 | 2019 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2021 |
| Pfizer | For profit | 1 | 0 | 1 | 2020 |
| Seoul National University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Swiss Group for Clinical Cancer Research | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Universidad Autonoma de Madrid | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Universidad Complutense de Madrid | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Geneva | Academic/Hospital | 1 | 0 | 1 | 2019 |
13 organizations
Page 1 / 1